🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join the Pharmacy SIG on Wednesday for a virtual roundtable which will delve into insights and key takeaways from the ASH Annual Meeting and 2025 Tandem Meetings. Discover and discuss the latest developments in the field, register for free: ow.ly/CMt450VpkOt

Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring | Duke Hematologic Malignancies & Cellular Therapy hubs.li/Q03j6WL80

Transformative therapies are changing the outlook for adults with sickle cell disease. This article compares options like matched sibling transplants, gene therapy and haploidentical BMT. Each approach offers benefits, and now, for many, there’s a choice. astctjournal.org/article/S2666-…

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study @BloodJournal ashpublications.org/blood/article/…

🚨 Latest paper from #COMMAND_consortium, reporting heterogeneity in clinical outcomes in #TP53m MPN, one of largest cohort of TP53m MPN: 1. Multihit TP53 had inferior outcome in chronic phase MPN, not so in MPN-AP or BP. Similar to our reports in HR-MDS/AML. 2. MH TP53 commonly

Check out FDA Oncology Approval Summary: Abatacept for prophylaxis of acute #GVHD. Highlights #ClinicalTrial and #RWD leading to approval. aacrjournals.org/clincancerres/…

At #ASCO25, Dr. Michael Wang shares results from the SYMPATICO study showing that first-line ibrutinib plus venetoclax is effective in patients with treatment-naive mantle cell lymphoma, including older adults and those with TP53 mutations. #EndCancer Michael Wang, MD

#ASCO25 #Ph_pos_ALL phase 1 study presented by Dr Marlise R. Luskin MD, MSCE Asciminib+Dasatinib+Prednisone followed by blinatumomab is safe and effective in achieving deep molecular remission. #leusm

The birth of cancer immunotherapies field in oncology followed this #bmtsm data from the 1970s, landmark discovery of GVHD following AlloHSCT is associated with less cancer relapse #ASCO25 Weiden et al, NEJM 1979, also check out nice summary below haematologica.org/article/view/1…

Are you thinking about manufacturing your own #CARtcell or developing a program for that at your own institution? Check out our ASTCT Talks podcast on this topic with the world expert on this, Dr Marcos de Lima #bmtsm #CellTherapy astct.org/Nucleus/Articl…

An investigator-initiated clinical trial evaluating #Ruxolitinib and #Fostamatinib for steroid-refractory chronic #GVHD is now accruing at Duke Cancer, one of few combinatorial regimens being tested, based on work from #SarantopoulosLab. PIs Chenyu Lin, MD Mitch Horwitz #BMTsm

ASTCT & CancerNetwork® organized an X Space hosted by Rahul Banerjee; Taha Al-Juhaishi & Muhammad Salman Faisal to discuss key presentations and abstracts of interest at the ⁠2025 ASCO Annual Meeting⁠. Listen now to catch up on what was discussed: ow.ly/4KJt50Wasku

The #MZL cohort of the TRANSCEND FL trial demonstrated high rates of durable responses with liso-cel in patients with relapsed/ refractory #MZL.International Conference on Malignant Lymphoma #18ICML hubs.li/Q03sh3GV0

This CIBMTR registry study published in Blood Neoplasia showed similar survival and faster neutrophil engraftment with #omidubicel transplantation vs. alternative stem cell sources, led by Duke Cancer faculty Chenyu Lin, MD Mitch Horwitz. #BMTsm #CordBlood ashpublications.org/bloodneoplasia…

🎙️ Just out on ASTCT’s #TitansOfTransplant: I sit down with my mentor and transplant trailblazer, Dr. Daniel Weisdorf. We trace the field's evolution and future frontiers, from sibling-only marrow harvests to cord-blood breakthroughs and next-gen GVHD prevention. Dan’s wisdom

U.S. FDA approves bispecific antibody, Lynozyfic (linvoseltamab), for treatment of relapsed/refractory #myeloma patients who have received 4 prior lines of therapy. investor.regeneron.com/news-releases/…  Learn more about LINKER-MM1 study. themmrf.org/mmrf-blogs/eha…

Don’t let the name fool you—we are here for all blood cancers, from A to Z (AML to Waldenström’s)